Tetra Bio-Pharma Inc. is pleased to provide investors with an update on our research, regulatory and commercial activities after closing the public placement.

Tetra Bio-Pharma Inc. is pleased to announce it has closed its previously announced short form prospectus offering of units of the Corporation, including the exercise in full of the Agents' over-allotment option.

Tetra Bio-Pharma Inc. is pleased to announce that its wholly owned subsidiary Panag Pharma Inc. has received a repayable Government of Canada contribution of $500,000 through the Atlantic Canada Opportunities Agency’s (ACOA) Business Development Program.

Tetra Bio-Pharma Inc. wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.

Tetra Bio-Pharma Inc. is pleased to announce the price of its marketed public offering of units of the Corporation previously announced on June 19, 2019. The Offering will be conducted at a price of $0.30 per Unit.

Tetra Bio-Pharma Inc. is pleased to announce that all matters presented for approval at the Corporation's annual general and special meeting of shareholders of the Corporation held in Montréal, province of Québec, on June 20, 2019, were approved.

Tetra Bio-Pharma Inc. is pleased to announce that it has filed and received a receipt for a preliminary short form prospectus in connection with a proposed offering of units for minimum gross proceeds of C$3,500,000 and maximum gross proceeds of C$7,000,000.

Tetra Bio-Pharma Inc. is pleased to provide investors with an update on our research, regulatory and commercial activities. This market update covers Tetra and its subsidiaries, Panag and Tetra Natural Health (TNH).

Proposed clinical development pathway confirmed by FDA Ottawa, Ontario, June 17, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development…

ORLEANS, Ontario, June 14, 2019 (GLOBE NEWSWIRE) - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSX VENTURE: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-based drug development and discovery, wishes…